Seminars in Hematology
Volume 45 , Pages S11-S16 , July 2008

Targeted Treatment and New Agents in Diffuse Large B-Cell Lymphoma

References 

  1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes (Non-Hodgkin's Lymphoma Classification Project). J Clin Oncol. 1998;16:2780–2795
  2. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize CM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002–1006
  3. Coiffier B, Feugier P, Mounier N, et al. Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients. J Clin Oncol. 2007;25:443s;(abstr 8009)
  4. Liu Q, Fayad L, Cabanillas F, Hyemeiske PB, Ayers GD, Hess M, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006;24:1582–1589
  5. A predictive model for aggressive non-Hodgkin's lymphoma (The International Non-Hodgkin's Lymphoma Prognostic Factors Project). N Engl J Med. 1993;329:987–994
  6. Chemoradiotherapy and peripheral stem cell transplantation compared with combination chemotherapy in treating patients with non-Hodgkin's lymphoma. http://clinicaltrials.gov/ct2/show/NCT00004031Accessed January 22, 2008
  7. Tholstrup D, de Nully BP, Jurlander J, Hansen M. Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphoma. Eur J Haematol. 2007;79:100–106
  8. Brusamolino E, Rusconi C, Montalbetti L, Gargantini L, Uziel L, Pinotti G, et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: A phase II study of feasibility and toxicity. Haematologica. 2006;91:496–502
  9. Schmits R, Schmitz N, Pfreundschuh M. The best treatment for diffuse large B-cell lymphoma: A German perspective. Oncology (Williston Park). 2005;19:16–25
  10. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rübe C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104:634–641
  11. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626–633
  12. Wunderlich A, Kloess M, Reiser M, Rudolph C, Truemper L, Britney S, et al. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: Results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2003;14:881–893
  13. Younes A. New treatment strategies for aggressive lymphoma. Semin Oncol. 2004;31:10–13
  14. Goldspiel BR. Chemotherapy dose density in early-stage breast cancer and non-Hodgkin's lymphoma. Pharmacotherapy. 2004;24:1347–1357
  15. Blayney DW, McGuire BW, Cruickshank SE, Johnson DH. Increasing chemotherapy dose density and intensity: Phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma. Oncologist. 2005;10:138–149
  16. Gregory SA, Trumper L. Chemotherapy dose intensity in non-Hodgkin's lymphoma: Is dose intensity an emerging paradigm for better outcomes?. Ann Oncol. 2005;16:1413–1424
  17. Halaas JL, Moskowitz CH, Horwitz S, Portlock C, Noy A, Straws D, et al. R-CHOP-14 in patients with diffuse large B-cell lymphoma: Feasibility and preliminary efficacy. Leuk Lymphoma. 2005;46:541–547
  18. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314–322
  19. Knight R. IMiDs: A novel class of immunomodulators. Semin Oncol. 2005;32:S24–S30
  20. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082–4085
  21. Meierhofer C, Dunzendorfer S, Wiedermann CJ. Theoretical basis for the activity of thalidomide. Biodrugs. 2001;15:681–703
  22. Wiernik PH, Lossos IS, Tuscano J, et al. Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory aggressive non-Hodgkin lymphoma. J Clin Oncol. 2007;25:454s;(abstr 8052)
  23. Kelley SK, Gelzleichter T, Xie D, Lee WP, Darbonne WC, Ouresti F, et al. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol. 2006;148:1116–1123
  24. Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res. 2005;65:8331–8338
  25. Advani R, Forero-Torres A, Furman R, et al. SGN-40 (Anti-huCD40 mAb) monotherapy induces durable objective responses in patients with relapsed aggressive non-Hodgkin's lymphoma: Evidence of antitumor activity from a phase I study. Blood. 2006;108:209a;(abstr 695)
  26. Lewis LS, McCormick RS, Kissler K, et al. The humanized anti-CD40 monoclonal antibody, SGN-40, potentiates chemotherapy regimens in NHL xenograft models via pro-apoptotic signaling. Blood. 2007;110:692a;(abstr 2342)
  27. Law CL, McEarchern JA, Cerveny CG, et al. The humanized anti-CD40 monoclonal antibody SGN-40 targets Hodgkin's disease cells through multiple mechanisms. Blood. 2005;106:425a;(abstr 1476)
  28. Lewis TS, Sutherland MSK, Jonas M, et al. The humanized anti-CD40 antibody, SGN-40, promotes apoptosis signaling and is effective in combination with standard therapies in lymphoma xenograft models. Blood. 2006;108:708a;(abstr 2499)
  29. Smith SM, Pro B, Smith S, et al. Molecular inhibition of mTOR with temsirolimus (TORISEL, CCI-779) is a promising strategy in relapsed NHL: The University of Chicago phase II consortium. Blood. 2006;108:703a;(abstr 2483)
  30. Georgakis GV, Yazbeck VY, Li Y, Younes A. The mTOR inhibitor temsirolimus (CCI-779) induces cell cycle arrest and autophagy in Hodgkin lymphoma (HL) cell lines and enhances the effect of PI3-kinase inhibitor LY294002. Blood. 2006;108:639a;(abstr 2259)
  31. Yazbeck VY, Georgakis GV, Li Y, Iwado E, Kondo S, Younes A. Molecular mechanisms of the mTOR inhibitor temsirolimus (CCI-779) antiproliferative effects in mantle cell lymphoma: Induction of cell cycle arrest, autophagy, and synergy with vorinostat (SAHA). Blood. 2006;108:706a;(abstr 2493)
  32. Reeder CB, Gornet MK, Habermann TM, et al. A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive non-Hodgkin lymphoma (NHL). Blood. 2007;110:44a;(abstr 121)
  33. Johnston PB, Ansell SM, Colgan JP, et al. mTOR inhibition for relapsed or refractory Hodgkin lymphoma: Promising single agent activity with everolimus (RAD001). Blood. 2007;110:753a;(abstr 2555)
  34. Johnston PB, Ansell SM, Colgan JP, et al. Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma. J Clin Oncol. 2007;25:454s;(abstr 8055)
  35. Martinez A, Bellosillo B, Bosch F, Ferrer A, Marcé S, Villamor N, et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol. 2004;164:501–510
  36. Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol. 2004;22:1682–1688
  37. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000;96:1921–1925
  38. Ansell SM, Arendt BK, Grote DM, Jelinek DF, Novak AJ, Wellik LE, et al. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia. 2004;18:616–623
  39. Tolcher AW, Antonia S, Lewis LD, et al. A phase I study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion to patients with advanced solid tumors. J Clin Oncol. 2006;24:124s;(abstr 3014)
  40. Study of YM155 in refractory diffuse large B-cell lymphoma (DLBCL) subjects. http://clinicaltrials.gov/ct2/show/NCT00498914Accessed January 22, 2008
  41. Wang M, Zhou Y, Zhang L, Nguyen CA, Romaguera J. Use of bortezomib in B-cell non-Hodgkin's lymphoma. Expert Rev Anticancer Ther. 2006;6:983–991
  42. O'Connor O, Wright J, Moskowitz C, et al. A multicenter experience with single agent bortezomib in non-Hodgkin's lymphoma reveals marked differences in sub-type sensitivity to proteasome inhibition. Blood. 2004;104:175a;(abstr 607)
  43. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:667–675
  44. Dunleavy K, Janik J, Gea-Banacloche J, et al. Phase I/II study of bortezomib alone and bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refractory aggressive B-cell lymphoma. Blood. 2004;104:389a;(abstr 1385)
  45. Leonard JP, Furman RR, Cheung Y-KK, et al. Phase I/II trial of bortezomib + CHOP-rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): Phase I results. Blood. 2005;106:147a;(abstr 491)
  46. Shipp MA, Ross KN, Tamayo P, Werg AP, Kutok JL, Aguiar RC, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68–74
  47. Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2007;25:1741–1746
  48. An study of patients with lymphoma who take R-CHOP and enzastaurin compared to patients who take R-CHOP only. http://clinicaltrials.gov/ct2/show/NCT00451178Accessed January 22, 2008
  49. A study of oral LY317615 in relapsed or refractory diffuse large B-cell lymphomas. http://clinicaltrials.gov/ct2/show/NCT00042666Accessed January 22, 2008
  50. PRELUDE: Study to investigate the prevention of relapse in lymphoma using daily enzastaurin. http://clinicaltrials.gov/ct2/show/NCT00332202Accessed January 22, 2008
  51. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006;24:166–173
  52. Crump M, Coiffier B, Jacobsen ED, et al. Oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed diffuse large B-cell lymphoma (DLBCL): Final results of a phase II trial. J Clin Oncol. 2007;25:702s;(abstr 18511)
  53. Vorinostat and decitabine in treating patients with relapsed, refractory, or poor-prognosis hematologic cancer or other diseases. http://clinicaltrials.gov/ct2/show/NCT00357708Accessed January 22, 2008
  54. Stopeck AT, Bellamy W, Unger J, Rimsza L, Iannone M, Fisher RI, et al. Phase II trial of single agent bevacizumab (Avastin) in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group Study S0108. J Clin Oncol. 2005;23:583s;(abstr 6592)
  55. Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J, et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma. 2006;47:998–1005
  56. A study of Avastin (bevacizumab) in combination with MabThera (rituximab) and CHOP chemotherapy in patients with diffuse large B-cell lymphoma. http://clinicaltrials.gov/ct2/show/NCT00486759Accessed January 22, 2008
  57. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003;63:4342–4346
  58. Rozados VR, Sanchez AM, Gervasoni SI, Berra HH, Matar P, Graciela SO. Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity. Ann Oncol. 2004;15:1543–1550
  59. Gille J, Spieth K, Kaufmann R. Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer. J Dtsch Dermatol Ges. 2005;3:26–32
  60. Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, et al. High-Dose celecoxib and metronomic “low-dose” cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res. 2006;12:5190–5198
  61. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–3127

 STATEMENT OF CONFLICT OF INTEREST: John P. Leonard, Research support/Principal Investigator: Biogen Idec, Cephalon, Genentech, GSK, Immunetics, Millennium, Seattle Genetics; Consultant/Scientific Advisory Board: Berlex, Biogen Idec, Bristol Myers, Cougar Biotechnology, Genentech, GSK, Millennium, Wyeth; Speaker's Bureau: Biogen Idec, Genentech, GSK, Millennium.

PII: S0037-1963(08)00120-0

doi: 10.1053/j.seminhematol.2008.07.004

Seminars in Hematology
Volume 45 , Pages S11-S16 , July 2008

Article Tools

* Image Usage & Resolution